Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach

British Journal of Clinical Pharmacology

Volumn 81, Issue 3, 2016, Pages 538-552

  Borghardt, Jens Markus ^a,b   Weber, Benjamin ^b   Staab, Alexander ^b   Kunz, Christina ^b   Formella, Stephan ^b   Kloft, Charlotte ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

inhalation; NONMEM; olodaterol; pharmacometrics; population pharmacokinetics; pulmonary absorption

Indexed keywords

OLODATEROL; BENZOXAZINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

ARTICLE; BLOOD SAMPLING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INFUSION; DRUG URINE LEVEL; GENERAL DEVICE; HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE; SOFT MIST INHALER; ADULT; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MALE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; URINE; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; BENZOXAZINES; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LUNG; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84959215097     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12780     Document Type: Article

References (45)

1. Patel JG, Nagar SP, Dalal AA,. Indirect costs in chronic obstructive pulmonary disease: A review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis 2014; 9: 289-300.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. Available from: Http://www.goldcopd.org/
3. Gibb A, Yang LP,. Olodaterol: First global approval. Drugs 2013; 73: 1841-6.
4. Olodaterol (Striverdi Respimat) for COPD. Med Lett Drugs Ther 2015; 57: 1-3.
5. Lipworth BJ,. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941-55.
6. Kane C, O'Neil K, Conk M, Picha K,. Inhalation delivery of protein therapeutics. Inflamm Allergy Drug Targets 2013; 12: 81-7.
7. Johnson EN, Druey KM,. Heterotrimeric G protein signaling: Role in asthma and allergic inflammation. J Allergy Clin Immunol 2002; 109: 592-602.
8. Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ,. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997; 37: 881-92.
9. Patton JS, Byron PR,. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
10. Ruge CA, Kirch J, Lehr CM,. Pulmonary drug delivery: From generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. Lancet Respir Med 2013; 1: 402-13.
11. Borghardt JM, Weber B, Staab A, Kloft C,. Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs. AAPS J 2015; 17: 853-70.
12. Tronde A, Bosquillon C, Forbes B,. The isolated perfused lung for drug absorption studies. In: Drug Absorption Studies: In Situ, In Vitro and In Silico Models, 1st edn, eds, Ehrhardt C, Kim K-J,. New York (NY), USA: Springer US, 2007; 135-63.
13. Bartels C, Looby M, Sechaud R, Kaiser G,. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach. Br J Clin Pharmacol 2013; 76: 868-79.
14. Parra-Guillen Z, Weber B, Sharma A, Freijer J, Retlich S, Borghardt JM, Troconiz IF,. Population pharmacokinetic analysis of tiotropium in healthy volunteers after intravenous administration and inhalation. J Pharmacokinet Pharmacodyn 2014; 41: S54.
15. Borghardt JM, Weber B, Staab A, Kunz C, Schiewe J, Kloft C, eds. Expanding the Mechanistic Knowledge about Pulmonary Absorption processes using a Population Pharmacokinetic Model for Inhaled Olodaterol. Respiratory Drug Delivery. Fajardo, Puerto Rico: Davis Healthcare International Publishing, LLC., 2014.
16. US Department of Health and Human Services; Food and Drug Administration FDA. Guidance for industry: Bioanalytical method validation, 2001; 1-22. Available from: Http://www.fda.gov/downloads/Drugs/./Guidances/ucm070107.pdf
17. Bonate PL,. Nonlinear mixed effects models: Theory. In: Pharmacokinetic-Pharmacodynamic Modeling and Simulation, 2nd edn, ed, Bonate PL,. New York (NY), USA: Springer, 2011; 233-301.
18. Lindbom L, Pihlgren P, Jonsson EN,. PsN-toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
19. Keizer RJ, Karlsson MO, Hooker A,. Modeling and simulation workbench for NONMEM: Tutorial on pirana, PsN, and xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2: E50.
20. Holford N, ed. The Visual Predictive Check-Superiority to Standard Diagnostic (Rorschach) Plots. PAGE Annual Meeting of the Population Approach Group in Europe, 2005; Pamplona, Spain.
21. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, Pieper M, Sieger P, Gantner F,. Functional and biochemical rationales for the 24-h-long duration of action of olodaterol. J Pharmacol Exp Ther 2011; 337: 600-9.
22. Patton JS, Fishburn CS, Weers JG,. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004; 1: 338-44.
23. Dershwitz M, Walsh JL, Morishige RJ, Connors PM, Rubsamen RM, Shafer SL, Rosow CE,. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 2000; 93: 619-28.
24. Borgström L, Bengtsson T, Derom E, Pauwels R,. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, turbuhaler®. Int J Pharm 2000; 193: 227-30.
25. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Haubetainger K,. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000; 89: 724-31.
26. Boxenbaum H, Battle M,. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995; 35: 763-6.
27. Shaykhiev R, Otaki F, Bonsu P, Dang DT, Teater M, Strulovici-Barel Y, Salit J, Harvey BG, Crystal RG,. Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo. Cell Mol Life Sci 2011; 68: 877-92.
28. Jones JG, Minty BD, Lawler P, Hulands G, Crawley JC, Veall N,. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; 1: 66-8.
29. Li XY, Rahman I, Donaldson K, MacNee W,. Mechanisms of cigarette smoke induced increased airspace permeability. Thorax 1996; 51: 465-71.
30. Minty BD, Jordan C, Jones JG,. Rapid improvement in abnormal pulmonary epithelial permeability after stopping cigarettes. Br Med J (Clin Res Ed) 1981; 282: 1183-6.
31. Sakagami M,. Insulin disposition in the lung following oral inhalation in humans: A meta-analysis of its pharmacokinetics. Clin Pharmacokinet 2004; 43: 539-52.
32. Kim CS, Hu SC,. Regional deposition of inhaled particles in human comparison between men and women. J Appl Physiol 1998; 84: 1834-44.
33. Pichelin M, Caillibotte G, Katz I, Martonen T,. Categorization of lung morphology based on FRC and height: Computer simulations of aerosol deposition. Aerosol Sci Tech 2012; 46: 70-81.
34. French MC, Wishart GN,. Isolated perfused rabbit lung as a model to study the absorption of organic aerosols. J Pharmacol Methods 1985; 13: 241-8.
35. Brown RA Jr, Schanker LS,. Absorption of aerosolized drugs from the rat lung. Drug Metab Dispos 1983; 11: 355-60.
36. Schanker LS, Mitchell EW, Brown RA Jr, Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab Dispos 1986; 14: 79-88.
37. Labiris NR, Dolovich MB,. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003; 56: 588-99.
38. Upton RN, Doolette DJ,. Kinetic aspects of drug disposition in the lungs. Clin Exp Pharmacol Physiol 1999; 26: 381-91.
39. Wanner A, Clinical perspectives: Role of the airway circulation in drug therapy. J Aerosol Med 1996; 9: 19-23.
40. International Commission on Radiological Protection. ICRP Publication 66 Human Respiratory Tract Model for Radiological Protection: New York, NY: Elsevier, 1994.
41. Ciciliani A-M, Wachtel H, Langguth P, eds. Comparing Respimat(R) Soft Mist(TM) Inhaler and DPI Aerosol Deposition by Combined In Vitro Measurements and CFD Simulations. Respiratory Drug Delivery. Fajardo, Puerto Rico: Davis Healthcare International Publishing, LLC., 2014.
42. Daniel WA, Wójcikowski J,. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur Neuropsychopharmacol 1999; 9: 483-91.
43. Dickens BF, Weglicki WB, Boehme PA, Mak TI,. Antioxidant and lysosomotropic properties of acridine-propranolol: Protection against oxidative endothelial cell injury. J Mol Cell Cardiol 2002; 34: 129-37.
44. MacIntyre AC, Cutler DJ,. The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 1988; 9: 513-26.
45. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.